Tesaro CEO says Zejula can be "every bit as meaningful" as Lynparza

9 November 2018

As far as PARP inhibitors are concerned, AstraZeneca (LSE: AZN) stole the show at the annual congress of ESMO this month, with the SOLO-1 trial of Lynparza (olaparib) showing striking data in the first-line maintenance setting for ovarian cancer patients.

Lonnie Moulder, chief executive of rival PARP blocker specialist Tesaro (Nasdaq: TSRO), tells The Pharma Letter the results were “outstanding” for patients, but demurs when asked whether it was too late for his program to catch up.

The Massachusetts, USA-based oncology specialist won approval in Europe for Zejula (niraparib) in late 2017, and it has been marketed in the USA since April 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK